Table 1.
DELFI performance for cancer detection
| Individuals analyzed | 95% specificity |
98% specificity |
||||||
|---|---|---|---|---|---|---|---|---|
| Individuals detected | Sensitivity | 95% CI | Individuals detected | Sensitivity | 95% CI | |||
| Healthy | 215 | 10 | - | - | 4 | - | - | |
| Cancer | 208 | 166 | 80% | 74%–85% | 152 | 73% | 67%–79% | |
| Type | Breast | 54 | 38 | 70% | 56%–82% | 31 | 57% | 43%–71% |
| Bile duct | 26 | 23 | 88% | 70%–98% | 21 | 81% | 61%–93% | |
| Colorectal | 27 | 22 | 81% | 62%–94% | 19 | 70% | 50%–86% | |
| Gastric | 27 | 22 | 81% | 62%–94% | 22 | 81% | 62%–94% | |
| Lung | 12 | 12 | 100% | 74%–100% | 12 | 100% | 74%–100% | |
| Ovarian | 28 | 25 | 89% | 72%–98% | 25 | 89% | 72%–98% | |
| Pancreatic | 34 | 24 | 71% | 53%–85% | 22 | 65% | 46%–80% | |
| Stage | I | 41 | 30 | 73% | 53%–86% | 28 | 68% | 52%–82% |
| II | 109 | 85 | 78% | 69%–85% | 78 | 72% | 62%–80% | |
| III | 33 | 30 | 91% | 76%–98% | 26 | 79% | 61%–91% | |
| IV | 22 | 18 | 82% | 60%–95% | 17 | 77% | 55%–92% | |
| X | 3 | 3 | 100% | 29%–100% | 3 | 100% | 29%–100% | |